Bactiguard Holding AB (publ) (BACTI_B) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, operator, and a warm welcome to everyone joining us for Bactiguard's second quarter presentation for 2026. I'm joined today by our CFO, Patrick Buck, and I'll take you through the quarter's strategic highlights and then hand over to Patrick for a closer look at the numbers before we open the line up for your questions. Today's title, Solid Performance Driven by Revenue Growth, captures exactly where we landed this quarter. Strong top line momentum across the business confirming that the slower start to the year was simply a matter of timing rather than any change in trend. So let's dive straight into the quarter. And let's start with the numbers. We're pleased to report second quarter net sales growth, excluding currency, of 16%. The main driver was a recovery in BD revenues alongside one of the strongest quarters our wound management portfolio has ever recorded. This quarter confirms that the softer start to the year was a matter of timing, not a change in trend, as I said, and our strategy execution is on track. Adjusted EBITDA came in at 5,600,000, up from SEK 4,400,000 a year ago, lifted by sales growth and continued cost discipline. It's a good illustration of how top line growth flows through to earnings in a scalable license business, and it gives us room to keep investing in future growth. Cash flow from operations amounted to $12,400,000 a clear step up from the $1,700,000 in the same quarter last year. Strategically, it was an eventful quarter two. We signed a new long term agreement that deepens our already thirty five year partnership with BD. We're seeing growth in the use of patients of Bactiguard coated implants with Zimmer Biomet, and we had strong momentum in our early partner dialogues. Let me take you through these one at a time. Let's t...